• All Categories
  • UK News
  • Europe
  • Global
  • R & D
  • Sales & Marketing
  • Manufacturing
  • Digital
  • Industry Insights
  • Appointments
  • Interviews
  • Features
  • Industry Facts
FDA approves AstraZeneca’s Tagrisso for lung cancer treatment
FDA approves AstraZeneca’s Tagrisso for lung cancer treatment

AstraZeneca has announced that the FDA has approved Tagrisso for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

4 March 2024Global
PharmaTimes
PharmaTimes

Www.pharmatimes.com/intcr

4 March 2024
$254m funding raised by Freenome for early cancer detection
$254m funding raised by Freenome for early cancer detection

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement of its single-cancer and tailored multi-cancer early detection tests developed on its multiomics platform.

4 March 2024R & D
International Clinical Trials
International Clinical Trials

Samedan ltd presents International Clinical Trials (ICT)

4 March 2024
Contents
Contents

Welcome to the March 2024 issue of Pharmafocus!

4 March 2024
FDA grants Fast Track designation to GSK’s chronic hepatitis B treatment
FDA grants Fast Track designation to GSK’s chronic hepatitis B treatment

GSK has announced that the FDA has granted fast track designation for bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis b.

4 March 2024Global
Comment
Comment

Considering the increase in measles cases and the benefits of vaccination

4 March 2024
PharmaRole
PharmaRole

Pharmarole.com

4 March 2024
FDA grants breakthrough therapy designation for J&J’s nipocalimab as HDFN treatment
FDA grants breakthrough therapy designation for J&J’s nipocalimab as HDFN treatment

Johnson & Johnson has announced that the FDA has granted breakthrough therapy designation for nipocalimab for the treatment of alloimmunised pregnant individuals at high risk of severe haemolytic disease of the foetus and newborn.

4 March 2024Global
FDA accepts argenx’s sBLA for Vyvgart Hytrulo for CIDP treatment
FDA accepts argenx’s sBLA for Vyvgart Hytrulo for CIDP treatment

Argenx has announced that the FDA has accepted a supplemental biologics license application (sBLA) for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for priority review.

4 March 2024Global
Domainex announces opening of new Biology Centre of Excellence in Cambridge, UK
Domainex announces opening of new Biology Centre of Excellence in Cambridge, UK

Domainex has announced that it has opened a new biology centre of excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions.

4 March 2024Manufacturing
Roche announces results from phase 3 study of allergy treatment, Xolair
Roche announces results from phase 3 study of allergy treatment, Xolair

Roche has announced data from stage 1 of the NIH-sponsored phase 3 outmatch trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.

4 March 2024R & D